Q4 2025 13F Holders as of 31 Dec 2025
-
Type / Class
-
Equity / RIGHT 10/15/2029
-
Total 13F shares
-
16,870,296
-
Share change
-
-105,484
-
Total reported value
-
$3,023,717
-
Price per share
-
$0.19
-
Number of holders
-
31
-
Value change
-
-$18,500
-
Number of buys
-
6
-
Number of sells
-
8
Institutional Holders of Drugs Made In America Acquisition Corp. - RIGHT 10/15/2029 (DMAAR) as of Q4 2025
As of 31 Dec 2025,
Drugs Made In America Acquisition Corp. - RIGHT 10/15/2029 (DMAAR) was held by
31 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
16,870,296 shares.
The largest 10 holders included
Polar Asset Management Partners Inc., Hudson Bay Capital Management LP, Harraden Circle Investments, LLC, HIGHBRIDGE CAPITAL MANAGEMENT LLC, TORONTO DOMINION BANK, ARISTEIA CAPITAL, L.L.C., MANGROVE PARTNERS IM, LLC, Linden Advisors LP, Clear Street Group Inc., and Shaolin Capital Management LLC.
This page lists
31
institutional shareholders reporting positions in this security
for the Q4 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.